JPMorgan Chase & Co. Issues Positive Forecast for Cellebrite DI (NASDAQ:CLBT) Stock Price

Cellebrite DI (NASDAQ:CLBT) had its price objective lifted by stock analysts at JPMorgan Chase & Co. from $24.00 to $28.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 12.36% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC increased their target price on Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Craig Hallum increased their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $22.14.

Cellebrite DI Stock Up 3.0 %

NASDAQ CLBT opened at $24.92 on Tuesday. The company has a 50-day simple moving average of $22.49 and a two-hundred day simple moving average of $19.05. Cellebrite DI has a 12-month low of $8.91 and a 12-month high of $26.30. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of -16.08, a PEG ratio of 3.72 and a beta of 1.47.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP bought a new position in shares of Cellebrite DI during the third quarter valued at approximately $27,000. Advisors Asset Management Inc. increased its position in Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares during the period. Pathway Financial Advisers LLC raised its holdings in Cellebrite DI by 1,583.8% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after purchasing an additional 4,118 shares in the last quarter. R Squared Ltd bought a new position in Cellebrite DI in the 4th quarter worth $100,000. Finally, Venturi Wealth Management LLC lifted its position in shares of Cellebrite DI by 28.6% in the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock worth $152,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.